| COLORS-Validate Study of Decision-Support Software for Surgical Sequencing in Colorectal Liver Metastases (NCT07760558) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-09-01 |
| Establishment of a Multi-omics Prediction Model for Early Triple-negative Breast Cancer Based on UPGRADE-TNBC Study (NCT07773818) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-08-06 |
| SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma (NCT07749859) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-08-01 |
| OVV-01 Intravenous and Intratumoral Injection Combined With AK112 for the Treatment of Advanced Solid Tumors (NCT07650825) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-08-01 |
| OVV-01 Injection Combined With AK112 Injection for the Treatment of Patients With Advanced Soft Tissue Sarcoma (STS) (NCT07650838) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-08-01 |
| Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC (NCT07711470) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-07-01 |
| Analysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor Therapy (NCT07596524) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-07-01 |
| Preoperative Radiotherapy and Anlotinib With or Without Penpulimab for Soft Tissue Sarcoma (NCT07612098) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-07-01 |
| Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer (NCT07689851) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-07-01 |
| Study of Wenyang Tongbi Formula in the Treatment of Chemotherapy-Induced Polyneuropathy (NCT07626528) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-07-01 |
| Distribution and Analysis of Metastatic Lymph Nodes in Colorectal Cancer Patients (DIAMOND) (NCT07306390) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-07-01 |
| Protein Supplementation for Radiation- Induced Oral Mucositis in Head and Neck Cancer Patients Receiving Radiotherapy (NCT07531563) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-07-01 |
| CIB In Vivo CAR-T Lentiviral Injection in Patients With Advanced Malignant Tumors (NCT07657585) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-07-01 |
| A Phase II Study of Radiation Therapy to Treat Refractory Breast Cancer (NCT07672743) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-06-30 |
| Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Multicenter Prospective Phase II Study (NCT07636824) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-06-16 |
| Risk-Stratified Hypofractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer (NCT07657442) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-06-15 |
| Inhaled mRNA Immunotherapy for Patients With Advanced Lung Cancer or Pulmonary Metastatic Solid Tumors (NCT07657611) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-06-10 |
| Multimodal Ablation Combined With Perioperative Tislelizumab and Chemotherapy for Resectable II-IIIB NSCLC (NCT07729670) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-06-01 |
| QH101 Cell Injection in Patients With Brain, Brain (Spinal) Meninges, and Spinal Cord Metastatic Malignant Solid Tumors (NCT07656103) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-05-31 |
| Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI (NCT07551414) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-05-30 |
| Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer (NCT06993506) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-05-28 |
| PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC (NCT07630363) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-05-14 |
| The Application of Symptoms Management Program Based on the Patient Reported Outcome After Esophagectomy (NCT07187154) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-05-02 |
| Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy (NCT07668037) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-05-01 |
| RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma (NCT07590024) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-05-01 |
| A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma (NCT07557251) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-05-01 |
| Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer (NCT07560358) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-05-01 |
| BR101 in Patients With Relapsed/Refractory Multiple Myeloma (NCT07537049) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-04-30 |
| Precision Radiotherapy for Refractory Brain Metastases: A Multicenter Study (NCT07586657) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-04-28 |
| Omitting Nasogastric Tube Decompression in Minimally Invasive Pancreaticoduodenectomy (NCT07370116) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-04-01 |
| A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Chemoimmunotherapy (NCT07530549) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-04-01 |
| Darolutamide ± ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate Cancer (NCT07476677) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-04-01 |
| Hypofractionated Radiotherapy for Postoperative Intermediate-Risk Head and Neck Squamous Cell Carcinoma (NCT07507058) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-04-01 |
| Sacituzumab Tirumotecan for Pancreatic Cancer (NCT07561463) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-04-01 |
| Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction (NCT07084519) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-03-27 |
| Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma (NCT07692152) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-03-17 |
| This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer. (NCT07249879) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-03-03 |
| Artificial Intelligence-assisted HER2 Expression Assessment in Urothelial Carcinoma Based on Imaging-pathology Omics (NCT07454941) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-03-02 |
| The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis (NCT07203729) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-03-01 |
| Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer (NCT07432594) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-03-01 |
| Detecting CREPT in Urine for Bladder Cancer Diagnosis and Monitoring (NCT07514897) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-03-01 |
| Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC (NCT07339839) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-03-01 |
| A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies (NCT07476378) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-03-01 |
| A Retrospective Real-World Study Based on RATIONALE-307 (NCT07478809) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-02-28 |
| Bevacizumab Plus Nab-paclitaxel and Tegafur Gimeracil Oteracil Potassium Capsule (S-1) as Second-line Treatment for Advanced Biliary Tract Cancer: a Phase Ⅱ Clinical Trial (NCT07719738) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-02-23 |
| Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients (NCT07366658) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-02-20 |
| Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer (NCT07317778) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-02-15 |
| Preoperative Hypofractionated RT + Immunotherapy & Surgery for Retroperitoneal Sarcoma (FUSION-02) (NCT07396116) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-02-12 |
| Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC) (NCT07413601) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-02-10 |
| An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases (NCT07461727) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-02-10 |
| Neoadjuvant Therapy With Tislelizumab for dMMR/MSI-H Stage II-III Colorectal Cancer (NCT07352280) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-02-01 |
| A Study of Postoperative Regional Nodal Radiotherapy in Intermediate-risk Breast Cancer (NCT07385365) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-02-01 |
| Response-Based Local Therapy for Regionally Advanced Breast Cancer (NCT07376538) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-02-01 |
| Remodeling of MHC-related Immune Microenvironment in MIBC After Neoadjuvant Therapy (NCT07440901) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-02-01 |
| A Phase I Platform Study of Target-Based Screened CAR-Macrophages for the Treatment of Advanced Malignant Tumors (NCT07409766) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-01-31 |
| Platform Study of VSV-Based Recombinant Oncolytic Viruses for the Treatment of Advanced Malignant Tumors (NCT07656116) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-01-29 |
| Multi-omics Analysis of Renal Cell Carcinoma Mechanisms; Drug Sensitivity Testing in Patient-Derived Cell-based Microtumors (NCT07351266) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-01-25 |
| Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors (NCT07396090) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-01-20 |
| Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC (NCT07724223) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-01-16 |
| BaiXiaoAi AI Companion for Cancer Patient Follow-up (NCT07396142) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-01-14 |
| Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors (NCT07349160) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-01-10 |
| Intraperitoneal SK-NK Cell Injection for Advanced Ovarian Cancer With Massive Ascites (NCT07435701) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-01-05 |
| Comparison of the Effect of Surgical Resection Based on Lesion Extent Before and After Neoadjuvant Therapy in Patients With Stage II-IIIB Non-Small Cell Lung Cancer: A Single-Center, Real-World, Open-Label Study (NCT07373899) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-01-01 |
| Dynamic Monitoring of Plasma ctDNA for Prognostic Assessment in Patients With B-Cell Non-Hodgkin Lymphoma (NCT07480837) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-01-01 |
| Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (NCT07307053) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-01-01 |
| Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC (NCT07618078) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-01-01 |
| Efficacy and Survival Analysis of Perioperative Treatment of Locally Advanced Gastric or Gastroesophageal Junction Cancer (NCT07429318) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-01-01 |
| Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma (NCT07480850) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-01-01 |
| An Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course Treatment (NCT06501976) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-12-31 |
| An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing (NCT07141771) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-12-31 |
| Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer (NCT07286695) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-12-31 |
| Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients (NCT07043894) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-12-25 |
| Prospective Randomized Controlled Clinical Study of Acupoint Application With Gutong Plaster in the Treatment of Moderate to Severe Cancer Pain (NCT07657390) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-12-25 |
| An Exploratory Clinical Study Evaluating the Safety and Efficacy of Allogeneic CAR-NK Cell Therapy for Metastatic Castration-resistant Prostate Cancer (mCRPC) (NCT07298239) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-12-18 |
| Safety and Efficacy of Intravenous IDOV-Immune in Patients With Advanced Solid Tumors (NCT07656090) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-12-18 |
| Impact of Anterior Urethral Suspension Combined With Pelvic Fascia Reconstruction During Robot-Assisted Radical Prostatectomy on Early Postoperative Urinary Continence Recovery: A Single-Center, Prospective, Single-Arm Clinical Study (NCT07725653) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-12-12 |
| A Platform Study of In Vivo CAR-T for Treating Advanced Malignant Tumors Based on Target Screening (NCT07395479) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-11-21 |
| A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation Model (NCT07239271) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-11-16 |
| Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo (NCT07239245) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-11-12 |
| Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC (NCT07232654) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-11-11 |
| CONNEctome-guided Navigation for Eloquent-area Tumor Surgery Trial (NCT07657403) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-11-01 |
| Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC (NCT07110103) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-10-31 |
| Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC (NCT07120282) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-10-28 |
| QL706 + Chemo ± Bevacizumab in Anti-PD-(L)1-Resistant R/M Cervical Cancer (NCT07186868) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-10-15 |
| Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma (NCT07156019) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-10-01 |
| Microfluidic Urinary Exosome-Based Diagnostic Model for Bladder Cancer (NCT07735858) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-10-01 |
| Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL (NCT07480863) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-10-01 |
| Neoadjuvant Chemotherapy Combined With Preoperative Radiotherapy for Locally Advanced Breast Cancer (NCT07164872) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-10-01 |
| Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases (NCT06848842) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-09-18 |
| A Phase I Study of CREPT-618 in Locally Advanced HCC (NCT07364357) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-09-15 |
| Study of Allogeneic Anti-PSMA CAR-NK Cell for Metastatic Castration-Resistant Prostate Cancer (NCT07156045) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-09-01 |
| Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer (NCT07088731) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-09-01 |
| SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer (NCT07132242) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-08-30 |
| Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients. (NCT07443397) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-08-29 |
| Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002) for Cancer Therapy-Induced Thrombocytopenia (CTIT) (NCT07110090) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-08-28 |
| Treatment Intermittent Periods Based on ctDNA-MRD（Circulating Tumor DNA-minimal Residual Disease） Status in Advanced HER2-Positive Breast Cancer (NCT07132502) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-08-25 |
| CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC (NCT07383246) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-08-25 |
| the Efficacy of MR-guided Online Adaptive Radiotherapy for Locally Advanced Rectal Cancer (NCT07080411) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-08-01 |
| A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen (NCT07099794) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-08-01 |
| A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations (NCT07048964) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-08-01 |